title: [Immunization campaign with 13-valent Pneumococcal Conjugate Vaccine in adults in Liguria Region, Italy: one year post-introduction preliminary results].
abstract: OBJECTIVE
  To assess the impact of the immunization program with 13-valent Pneumococcal Conjugate Vaccine (PCV13) in adults, from October 2013 in Liguria, Italy, both in terms of effectiveness, and tolerability and safety.
  
  
  METHODS
  First study: descriptive epidemiology of the clinical burden of lower respiratory tract infections (LRTI) and the role of risk factors or co-morbidity in adults >18 years of age. Second study: crossover evaluation of the effect of PCV13 introduction in adults aged ≥70 years, in terms of ED accesses for LRTI, obtained by a Syndrome Surveillance System (SSS) operating in Liguria from 2007. Third study: evaluation of safety and tolerability profile of PCV13 in terms of local and systemic solicited and unsolicited adverse events.
  
  
  RESULTS
  During pre-PCV period, annual cumulative incidence of ED accesses for LRTI was equal to 7/1000 and 2% in ≥65 and ≥85 year adults, respectively. In ≥65 years adults, more than 70% of identified subjects has at least one risk condition. A significant reduction in the incidence of ED accesses for LRTI in the vaccinated population, compared to non-vaccinated subjects, has already been observed: the preventive fraction, adjusted for age and seasonality, was estimated to be nearly 20%. PCV13 had a good safety and tolerability profile: rates of local (32%) and systemic (22%) solicited reactions resulted generally lower than those registered in clinical trials previously performed in the elderly.
  
  
  CONCLUSIONS
  Preliminary PCV13 assessments regarding safety and tolerability profile, together with the initial effects of the immunization program in terms of reduction of ED accesses for LRTI, confirmed the effectiveness of current Liguria Region recommendations for the prevention of pneumococcal disease in adult population.
authors.affiliation: Dipartimento di scienze della salute, Università degli studi di Genova. andrea.orsi@unige.it.
authors.forename: Andrea
authors.initials: A
authors.lastname: Orsi
authors.forename: Filippo
authors.initials: F
authors.lastname: Ansaldi
authors.forename: Paolo
authors.initials: P
authors.lastname: Durando
authors.forename: Valter
authors.initials: V
authors.lastname: Turello
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Icardi
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D005260:Female; D006801:Humans; D017589:Immunization Programs / Q000706:statistics & numerical data*; D015994:Incidence; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000009:adverse effects; D011018:Pneumonia, Pneumococcal / Q000453:epidemiology / Q000517:prevention & control; D015397:Program Evaluation; D012307:Risk Factors; D014611:Vaccination; D055815:Young Adult
chemical_list: C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines